ASBP

Company Overview — What Does Aspire Biopharma Holdings, Inc. Do?

Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico. Aspire Biopharma Holdings, Inc. (ASBP) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Kraig T. Higginson. With a market capitalization of $5M, ASBP is one of the notable companies in the Healthcare sector.

Aspire Biopharma Holdings, Inc. (ASBP) Stock Rating — Reduce (April 2026)

As of April 2026, Aspire Biopharma Holdings, Inc. receives a Reduce rating with a composite score of 34.5/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ASBP ranks #3,504 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Aspire Biopharma Holdings, Inc. ranks #546 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ASBP Stock Price and 52-Week Range

Aspire Biopharma Holdings, Inc. (ASBP) currently trades at $1.04. The stock lost $0.16 (13.3%) in the most recent trading session. The 52-week high for ASBP is $2.45, which means the stock is currently trading -57.6% from its annual peak. The 52-week low is $0.05, putting the stock 2151.1% above its annual trough. Recent trading volume was 85K shares, suggesting relatively thin trading activity.

Is ASBP Overvalued or Undervalued? — Valuation Analysis

Aspire Biopharma Holdings, Inc. (ASBP) carries a value factor score of 7/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-sales ratio is 5967.57x, compared to 1.66x for the average Healthcare stock.

At current multiples, Aspire Biopharma Holdings, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Aspire Biopharma Holdings, Inc. Profitability — ROE, Margins, and Quality Score

Aspire Biopharma Holdings, Inc. (ASBP) earns a quality factor score of 9/100, signaling below-average profitability metrics relative to the broader market. Return on assets (ROA) comes in at -1523.4% versus the sector average of -33.1%.

On a margin basis, Aspire Biopharma Holdings, Inc. reports gross margins of 46.0%, compared to 71.5% for the sector. The operating margin is -129581.1% (sector: -66.1%). Net profit margin stands at -209331.8%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ASBP Debt, Balance Sheet, and Financial Health

Balance sheet data for ASBP is evaluated through our stability factor. The current ratio is 0.17x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $6M. Cash and equivalents stand at $2M.

ASBP has a beta of -0.45, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Aspire Biopharma Holdings, Inc. is 26/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Aspire Biopharma Holdings, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Aspire Biopharma Holdings, Inc. reported revenue of $884 and earnings per share (EPS) of $-16.38. Net income for the quarter was $-20M. Gross margin was 46.0%. Operating income came in at $-2M.

In FY 2025, Aspire Biopharma Holdings, Inc. reported revenue of $6,202. Net income for the quarter was $-24M. Operating income came in at $-19M.

In Q3 2025, Aspire Biopharma Holdings, Inc. reported revenue of $884 and earnings per share (EPS) of $-0.04. Net income for the quarter was $-2M. Operating income came in at $-1M.

In Q2 2025, Aspire Biopharma Holdings, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.04. Net income for the quarter was $-2M. Operating income came in at $-799,890.

Over the past 8 quarters, Aspire Biopharma Holdings, Inc. has demonstrated a growth trajectory, with revenue expanding from $0 to $884. Investors analyzing ASBP stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ASBP Dividend Yield and Income Analysis

Aspire Biopharma Holdings, Inc. (ASBP) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ASBP Momentum and Technical Analysis Profile

Aspire Biopharma Holdings, Inc. (ASBP) has a momentum factor score of 75/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 69/100 reflects moderate short selling activity.

ASBP vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Aspire Biopharma Holdings, Inc. (ASBP) ranks #546 out of 838 stocks based on the Blank Capital composite score. This places ASBP in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ASBP against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ASBP vs S&P 500 (SPY) comparison to assess how Aspire Biopharma Holdings, Inc. stacks up against the broader market across all factor dimensions.

ASBP Next Earnings Date

No upcoming earnings date has been announced for Aspire Biopharma Holdings, Inc. (ASBP) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ASBP? — Investment Thesis Summary

The quantitative profile for Aspire Biopharma Holdings, Inc. suggests caution. The quality score of 9/100 flags below-average profitability. The value score of 7/100 indicates premium valuation. Price momentum is positive at 75/100, suggesting the trend favors buyers. High volatility (stability score 26/100) increases portfolio risk.

In summary, Aspire Biopharma Holdings, Inc. (ASBP) earns a Reduce rating with a composite score of 34.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ASBP stock.

Related Resources for ASBP Investors

Explore more research and tools: ASBP vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ASBP head-to-head with peers: ASBP vs AZN, ASBP vs SLGL, ASBP vs VMD.